The family protecting HPH116 and related compounds, in Anti-allergic field, Anti-inflammatory field :

Method for inhibiting cytokine production by cells

Australian patent n° 13276/99
Canadian patent n° 2312023
European patent n° 98956724.3
Japanese patent n° 2000-522922
US patent n° 09/555258
   

Under H-Phar collaboration contract, Michel Goldman and colleagues at the Universite Libre of Brussels discovered that the drug also has immunosuppressive effects and may be useful in the treatment of transplant rejection, autoimmune diseases and allergic disorders. Goldman's team tested azodicarbonmide in mice carrying skin transplants and found that it delays the time to rejection of these allografts by inhibiting the proliferation of both CD4 T cells (helper cells) and CD8 T cells (killer cells), in addition to decreasing the release of cytokines from these immune cells.

Moreover analogue of Azodicarbonamide have been tested and show interesting results

2015 Unpublished data shows activity in various fields

The protein hydroxysteroid (17-beta) dehydrogenase 10 is implicated in the development of Alzheimer's disease as interacting with amyloid protein precursor

The development of this therapeutically field represent a formidable challenge for H-Phar’s next years

 

 

All data are of course auditable

 

 
 
 
H-Phar™ and the H-Phar logo are registred trademarks of H-Phar Company™